CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.09
+0.03 (0.42%)
At close: Jan 14, 2026, 4:00 PM EST
7.15
+0.06 (0.85%)
After-hours: Jan 14, 2026, 7:58 PM EST
CorMedix Employees
As of December 31, 2024, CorMedix had 65 total employees, including 64 full-time and 1 part-time employees. The number of employees decreased by 18 or -21.69% compared to the previous year.
Employees
65
Change (1Y)
-18
Growth (1Y)
-21.69%
Revenue / Employee
$3,296,980
Profits / Employee
$2,499,989
Market Cap
558.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | -18 | -21.69% |
| Dec 31, 2023 | 83 | 42 | 102.44% |
| Dec 31, 2022 | 41 | 11 | 36.67% |
| Dec 31, 2021 | 30 | -5 | -14.29% |
| Dec 31, 2020 | 35 | 5 | 16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRMD News
- 1 day ago - CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 days ago - Why is CorMedix stock crashing today: is it worth buying on the dip? - Invezz
- 6 days ago - CorMedix Therapeutics Announces Leadership and Board Updates - GlobeNewsWire
- 6 days ago - CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates - GlobeNewsWire
- 27 days ago - CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath - GlobeNewsWire
- 2 months ago - CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating - Seeking Alpha
- 2 months ago - Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire